Compare · LUCD vs MDLN
LUCD vs MDLN
Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCD and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.72B, about 642.3x LUCD ($75.9M).
- MDLN has been more active in the news (24 items in the past 4 weeks vs 7 for LUCD).
- MDLN has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- Lucid Diagnostics Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $75.9M
- $48.72B
- 1M return
- -
- +6.28%
- 1Y return
- -
- -9.03%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 7
- 24
- Recent ratings
- 6
- 25
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest LUCD
- PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
- Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- Oil Above $100 Puts Penny Stocks in Focus
Latest MDLN
- Large owner Cp Circle Ml Holdco Gp, Llc converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Mozart Coinvestment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- Large owner Tc Group Cayman Investment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Group Inc. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. converted options into 12,128,729 shares and disposed of 12,128,729 units of Class B Common Stock (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- SEC Form 424B4 filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers